
Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
IN VIVO
Start-Up
The RPM Report
Medtech Insight
Sign up
now
|
|

|
|
|
|
|
Register for
PSO &
BIO-Windhover |
|
|
|
|
|
|
|
Big Pharma Mergers:
Why? And What Will They Mean to
You?
with
Mervyn Turner, PhD - Chief Strategy Officer & SVP, WW Licensing and External
Research, Merck & Co.
Pharmaceutical Strategic Outlook
presents Merck, Pfizer and Wyeth senior executives and MORE!
What a roller coaster since Pfizer announced its acquisition of Wyeth, followed
a month later, by Merck buying Schering-Plough! PSO is proud to
announce its blockbuster plenary session on this hot topic. After all, the deals
share key commonalities (e.g., driving earnings growth across genericization
cliffs with synergies), but they’re also philosophically very different – and
could mean very different things for partnering going forward. PSO
bring in the deals’ strategic bosses and chief engineers to discuss why they did
them and how they’ll affect their dealmaking going forward.
Who will you hear from?
- Geno Germano, President U.S. and General Manager Pharmaceuticals, Wyeth
- Rod MacKenzie, Senior Vice President, Head of Worldwide Discovery Research, Pfizer Inc.
- Jean-Marc Huet, Senior Vice President & Chief Financial Officer, Bristol-Myers Squibb
- Corey Goodman, President, Biotherapeutics and Bioinnovation Center, Pfizer
- Paul Clancy, Executive Vice President, Finance and Chief Financial Officer , Biogen IDEC*
- Tony Rosenberg, Head of Global Business Development & Licensing, Novartis Pharma AG
- James J. Dolan, Senior Vice President, Licensing & Business Development, Purdue Pharma
- Adelene Q. Perkins, EVP & Chief Business Officer, Infinity Pharmaceuticals Inc.
- Dennis Purcell, Senior Managing Partner, Aisling Capital
- Francesco De Rubertis, Partner, Index Ventures
- Michael Ross, PhD, Managing Partner, SV Life Sciences
- Ryan Mueller, Managing Director, Monument Group
- David Lacey, MD, Senior Vice President, Head of Research, Amgen*
- Christoph Westphal, CEO, Sirtris Pharmaceuticals, a GSK Company, Head of the CEEDD (Center of Excellence for External Drug Discovery, Glaxosmithkline
- Deborah Dunsire, President & CEO, Millennium, a Takeda Pharmaceuticals Company
- Alexander J. Denner,Managing Director, Icahn Partners LP
- William Slattery, Partner, Deerfield Management Company
- Alan Eisenberg, EVP, Emerging Companies and Business Development, BIO
- Tyrone Edwards, President, The Thompson Consulting Group of Springhouse; Former
SVP Sales & Operations, Merck & Co.
- Richard Smith, Partner, Life Science Practice, Edwards Angell Palmer & Dodge LLP
*invited
What's on the agenda?
Windhover’s must-attend event examines and
explains the most important strategic alliances of the last year, and looks
ahead to what the industry can expect in the upcoming year.
- Big Pharma Mergers: Why? And What Will They Mean to You?
- Standalones: Can biotechs be successfully run as standalones within Pharma?
- Panel with Heads of Discovery: What is the role of discovery in new Pharma structures?
- The Future of Primary Care
- The Impact of Obama’s Administration on Pharma
- Past Big Pharma Executive Perspective: What should Big Pharma do next?
- Interesting Deal Structures: Keeping our options open and shelters for the financial storm
- What's Next for Private Exits? Implications and complications for growing private biotechs
- Option Deals, Opt-Ins and Options to Acquire
- Dealmaking Trends, Data and Analysis
Roger Longman, Managing Partner, Windhover Information
|
Also included are the following top-level workshops:
"Rebuilding an Industry - One
opportunity at a time"
Presented by NovaQuest. More Information. |
 |
"Two points of View: the licensing candidate value proposition from the emerging company and big pharma perspective"
Presented by The Mattson Jack Group. More Information. |
 |
"Biotechs on the Brink:
Only the Focused Can Survive"
Presented by Easton Associates. More Information. |
 |
|
Click to download the brochure (PDF)

|
Please make plans to join us in New York this April for
Pharmaceutical Strategic Outlook and
BIO-Windhover, FDC-Windhover's premier strategic and partnering
conferences being held concurrently this year. Some plenary sessions and
networking events are open to attendees of both conferences. Other program
elements (such as partnering or panel sessions) are only open to registrants of
one or the other conference.
Take the opportunity to not only
find the partners you need, but to learn the latest successful strategies from top dealmakers, all in one week! Receive a
30% discount when you
register for both. |
|
Why should I attend?
Windhover's Pharmaceutical Strategic Outlook is THE MOST strategic level
conference for biopharma deal structure and strategy – and simply the event
where you’ll meet the most important people in the business!
At PSO you can:
- Meet your potential partner and find out how to approach them
- Benchmark your dealmaking against the best and the brightest
- Learn the deal values and deal specifics that let you calibrate deal-making
metrics
- Get key trend analysis on new business models, deal structures and deal
failures
- Maximize your strategic alliance opportunities by meeting business development
leaders who’ll share practical advice and strategies on how to structure
successful deals
- Walk away with practical, real-life lessons from some of the most experienced
dealmakers in the industry on how they evaluate opportunities and risk
Who will I meet?

Who can I network with?
Aisling
Capital
Ajinomoto Co. Inc.
Alba Therapeutics Corp.
Antisoma PLC
AstraZeneca
Asubio Pharmaceuticals Inc.
Bayer Healthcare Pharmaceuticals
Bayer Schering Pharma AG
Bristol Myers Squibb Co.
BSI Healthcapital SA
Camurus
Capital Royalty
Cequent Pharmaceuticals Inc.
Chiesi Pharmaceuticals Inc.
Chugai Pharmaceutical Co. Ltd.
Cipher Pharmaceuticals Ltd
CoNCERT Pharmaceuticals
Covidien |
Daiichi
Sankyo
Eisai
Eli Lilly & Co.
Enzo Therapeutics Inc.
Esteve Group
Galderma
Glaxosmithkline
Johnson & Johnson
KBI BioPharma Inc.
Kyowa Pharmaceuticals
Kyorin USA Inc.
McKinsey & Co. Inc.
Medimmune
Merck & Co. Inc.
Millennium Pharmaceuticals Inc.
Montgomery & Co.
NicOx SA
Novartis Pharma AG
|
Novartis
Pharmaceuticals Corp.
OncoMed Pharmaceuticals Inc.
OSI Pharmaceuticals Inc.
Pfizer Inc.
Portola Pharmaceuticals
Purdue Pharma LP
Salix Pharmaceuticals
Sanofi-Aventis
Sirtris
Smith & Nephew Inc.
Solvay Pharmaceuticals Inc.
Takeda Research Investment
Targacept Inc.
UCB SA
Vifor Pharma Aspreva
Vitae Pharmaceuticals
Wyeth
|
Maximize your strategic alliance opportunities
by hearing CEOs, senior R&D and
senior business development executives share lessons learned, practical advice
and strategies on how to build your R&D pipeline – both internally and
externally. Take away the newest strategies and tactics that you can apply to
your company’s dealmaking efforts immediately!
PSO offers you an unbeatable line-up of Big Pharma and biotech speakers to
forecast trends and analyze changes in alliances and M&A. You’ll hear from, and
be able to quiz top industry executives and dealmakers.
PSO gathers top thinkers to grapple with the fundamental challenges facing
biotech and pharma – equipping dealmakers like you with the insights,
information and practical advice you'll need to strike successful deals. And as
always, you’ll be able to network and exchange ideas with an elite group of your
peers, your colleagues, your partners and your competitors.
See you at the
Marriott Marquis, New York City, this April 13-15!
|
|
Sponsors |
|
Gold Industry Sponsors


Industry Sponsors



Technology Sponsors
 |
Global Sponsors




Workshop Sponsors


 |
Major Supporting Publications




Media Sponsors



Regional Supporting Organization
 |
|
|
 |
|
|
|
|
| |
 |
Pfizer's Ambitions in the Off-Patent World
The pending purchase of Wyeth will accelerate Pfizer's transformation from a mass marketer of superstar drugs into a . . .[MORE
. . .] (IN VIVO)
The Epigenetics (R)evolution
Constellation and EpiZyme are poised to become dominant players in the unfolding field of epigenetics, an area of biology . . . [MORE. . .] (Start-Up)
A New Era Dawns in Physician-Device Industry Relationships
The push for transparency in the health care industry has moved beyond initial regulations focused on hospital safety . . .[MORE. . .] (Medtech Insight)
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that . . .[MORE. . .] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|